Clinical Trial Translation Services: A Sponsor's Guide to Compliance and Linguistic Validation
Only 2.71% of registered clinical trials accommodate a language other than English. Here's what the regulatory bodies actually require, what the comprehension data shows, and what to ask before you sign a translation partner.
Only 2.71% of clinical trials registered on ClinicalTrials.gov between 2019 and 2020 specifically mentioned accommodating a language other than English — while 18.98% required participants to read, speak, or understand English to take part at all (PLOS Medicine, 2021). That gap isn't a rounding error. It's the difference between the population a trial is designed to serve and the population it actually recruits.
For sponsors and CROs, clinical trial translation services aren't a formatting step tacked on before submission — they sit inside the trial's risk profile, next to recruitment, retention, and data integrity.
The numbers worth knowing
| Finding | Detail | Source |
|---|---|---|
| Translation accommodation gap | 18.98% of trials required English proficiency; only 2.71% mentioned translation accommodation | PLOS Medicine |
| Federally vs. industry-funded | 4.68% of federally funded trials accommodated other languages, vs. 0.49% of industry-funded trials | PLOS Medicine |
| Wrong-language consent signing | Non-English speakers signed consent in the wrong language in 43.8% of industry-sponsored studies and 72.6% of non-industry studies | Torjoman, 2025 |
| When translations were available | Only 3% of wrong-language signings occurred when a translation in the patient's primary language actually existed | Torjoman, 2025 |
| ICF readability, once translated | 30 translated psychiatric ICFs averaged a grade 13.66 reading level — college-level — despite being meant for general patients | PMC, NIH |
Read together, these numbers point to the same failure mode: translation is treated as available-if-convenient rather than built into the trial design — and even when it happens, it isn't always validated for whether a patient can actually understand it.
Why "translation" and "linguistic validation" aren't the same thing
A protocol translation has to satisfy an ethics committee. An informed consent form has to be understandable to a patient with no medical background — at a reading level that reflects how people actually read, not grade-13 prose. A patient-reported outcome (PRO) measure has to preserve conceptual meaning across cultures, or the data it produces won't be comparable across sites.
Linguistic validation is the structured process built for exactly this problem, following the ISPOR methodology used across the industry:
| Stage | What it does |
|---|---|
| Forward translation | Two independent translators produce initial versions |
| Reconciliation | A third linguist merges them into a single reconciled version |
| Back-translation | An independent translator, blind to the source, translates back into the original language |
| Cognitive debriefing | Target-language patients are interviewed to confirm they understand the intended meaning, not just the words |
| Harmonisation | All language versions are checked against each other so the instrument means the same thing everywhere it's deployed |
Skip a stage, and the risk isn't abstract: it's a query from an ethics committee, an audit finding, or PRO data from two country cohorts that can't legitimately be pooled because the instrument didn't mean the same thing to both groups.
Regulatory expectations, by authority
| Authority | Requirement |
|---|---|
| FDA (US) | Consent must be in "language understandable to the subject" |
| OHRP (US) | Explicitly mandates translated ICFs for non-English-speaking participants |
| EMA (Europe) | Requires translated documents for all official languages in the trial region |
| PMDA (Japan) | Recommends translation of all patient-facing documents into Japanese |
| IRBs / Ethics Committees | Routinely request back-translations and documented translator credentials as part of approval |
What to actually ask a translation partner
- Does machine translation touch regulated content at any stage — including draft passes, not just the final deliverable?
- Can they name the linguistic validation stages they run, as distinct, auditable deliverables — not "extra QA" bundled into one step?
- Do they use a fixed pool of subject-matter linguists per language pair, or whoever's available that week? Consistency across a multi-year trial depends on this.
- What professional accountability stands behind the work — professional body membership, insurance, a named certification — if a translation is challenged during an inspection?
- Can they handle simultaneous multi-locale rollouts without dropping to machine-assisted shortcuts under deadline pressure?
TranslationsInLondon Ltd is an ITI Corporate Member operating a strict human-only translation policy — no machine translation touches any stage of clinical or regulated content.
Our linguistic validation and cognitive debriefing work has included harmonisation reporting across 10+ locales in a single project (Greek, French, Serbian, Italian, Hungarian, Spanish, Polish, Turkish, Russian, and Portuguese), delivered through a partnership with GRC Health. Every translator works from a fixed, vetted pool per language pair — see our approach to certified translation and clinical interpreting.
Planning a multi-country trial?
Let's talk through your language plan before it becomes a submission risk.
Get in touch